These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 8523584

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN.
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [Abstract] [Full Text] [Related]

  • 4. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [Abstract] [Full Text] [Related]

  • 5. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
    Vázquez-Rosales G, García Lerma JG, Yamamoto S, Switzer WM, Havlir D, Folks TM, Richman DD, Heneine W.
    AIDS Res Hum Retroviruses; 1999 Sep 01; 15(13):1191-200. PubMed ID: 10480632
    [Abstract] [Full Text] [Related]

  • 6. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.
    Tuaillon E, Gueudin M, Lemée V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J.
    J Acquir Immune Defic Syndr; 2004 Dec 15; 37(5):1543-9. PubMed ID: 15577405
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S, Bakhanashvili M, Tal R, Hughes SH, Boyer PL, Hizi A.
    AIDS Res Hum Retroviruses; 1994 Aug 15; 10(8):939-46. PubMed ID: 7529032
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
    Havlir DV, Eastman S, Gamst A, Richman DD.
    J Virol; 1996 Nov 15; 70(11):7894-9. PubMed ID: 8892912
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission.
    Dornadula G, Zhang H, Shetty S, Pomerantz RJ.
    Virology; 1999 Jan 05; 253(1):10-6. PubMed ID: 9887314
    [Abstract] [Full Text] [Related]

  • 14. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R, Yokoyama M, Sato H, Reilly C, Mansky LM.
    J Virol; 2005 Sep 05; 79(18):12045-57. PubMed ID: 16140780
    [Abstract] [Full Text] [Related]

  • 15. Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004.
    Parham L, de Rivera IL, Murillo W, Naver L, Largaespada N, Albert J, Karlsson AC.
    AIDS Res Hum Retroviruses; 2011 Oct 05; 27(10):1055-9. PubMed ID: 21417948
    [Abstract] [Full Text] [Related]

  • 16. The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Emini EA, Byrnes VW, Condra JH, Schleif WA, Sardana VV.
    Arch Virol Suppl; 1994 Oct 05; 9():11-7. PubMed ID: 7518271
    [Abstract] [Full Text] [Related]

  • 17. Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1.
    Quan Y, Rong L, Liang C, Wainberg MA.
    J Virol; 1999 Aug 05; 73(8):6700-7. PubMed ID: 10400767
    [Abstract] [Full Text] [Related]

  • 18. Natural endogenous reverse transcription of HIV-1.
    Zhang H, Dornadula G, Pomerantz RJ.
    J Reprod Immunol; 1998 Dec 05; 41(1-2):255-60. PubMed ID: 10213314
    [Abstract] [Full Text] [Related]

  • 19. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen IS, Stevenson M, Tarpley WG.
    Proc Natl Acad Sci U S A; 1993 May 15; 90(10):4713-7. PubMed ID: 7685109
    [Abstract] [Full Text] [Related]

  • 20. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J.
    Proc Natl Acad Sci U S A; 1991 Dec 15; 88(24):11241-5. PubMed ID: 1722324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.